John Hainsworth is a Lung Cancer Treatments and Mutations physician affiliated with Sarah Cannon Research Institute. OpenAlex indexes 789 publications with 58,030 citations (h-index 99); ClinicalTrials.gov lists 44 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Data verified 11 Oct 2026
Overview
Updated 14 Oct 2026
John Hainsworth, MD, is affiliated with Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN. The public record shows 789 publications with 58,030 citations (h-index 99), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies. It also documents an investigator role on 44 registered clinical trials, industry payments reported by 1 companies, 1 NIH-funded awards (1987–1989).
- Most recent indexed publication: 2018 · Cancer
- Top research focus: Lung Cancer Treatments and Mutations
- 44 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 409.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 44 registered studies on ClinicalTrials.gov. The most recent:
- Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
Sponsor: SCRI Development Innovations, LLC
- Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Sponsor: SCRI Development Innovations, LLC
- Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel
Sponsor: SCRI Development Innovations, LLC
Industry payments
Updated 14 Oct 2026
1 company reported payments to CMS in program years 2025–2025. These are public disclosures, not judgments. The latest:
- Stemline Therapeutics Inc.Program year20251 payment
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 1987–1989 per NIH RePORTER. The latest:
- ORAL SPIROGERMANIUM IN ADVANCED CANCER REFRACTORY TO STANDARD TREATMENT
Vanderbilt University
FY1988M01RR000095
Congress activity
Updated 14 Oct 2026
194 congress contributions (1993–2024) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 1209: Tumor informed circulating tumor DNA monitoring for early treatment response and survival outcomes on trastuzumab + pertuzumab
AACR Annual Meeting
AACR2024Co-author - Abstract CT032: Activity and safety of alectinib for ALK-altered solid tumors from MyPathway
AACR (meeting unresolved)
AACR2022Co-author - Abstract LB012: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort
AACR (meeting unresolved)
AACR2021Presenting authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)- 01Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerArticle10,993 citations2004
- 02Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyArticle4,589 citations2012
- 03Abiraterone and Increased Survival in Metastatic Prostate CancerArticle4,402 citations2011
- 04Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaArticle1,463 citations2012
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancerhistoryproject.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerhistoryproject.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
David Spigel, MD
Sarah Cannon Research Institute
Howard Burris, MD
Sarah Cannon Research Institute
Jesus Berdeja, MD
Sarah Cannon Research Institute
Denise A. Yardley
Sarah Cannon Research Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center